A phase 2, open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large b-cell lymphoma (LOTIS-9)
Westin, J. Burke, J. M. Chapman, A. E. Kilavuz, T. Xu, C. Shmuely, Y. Radford, John A
Westin, J.
Burke, J. M.
Chapman, A. E.
Kilavuz, T.
Xu, C.
Shmuely, Y.
Radford, John A
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Westin J, Burke JM, Chapman AE, Kilavuz T, Xu C, Shmuely Y, et al. A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9). Clinical Lymphoma Myeloma & Leukemia. 2022 Oct;22:S368-S. PubMed PMID: WOS:000897948100398.